RE:RE:Just inWe all know that the multiples being paid for assets is lower than one year ago. Also, the multiple depends on the quality of the assets... i.e. cash flow contribution. CXR under PE can take advantage of the discount given to pharma assets at this time if they were within PE.
Craigbad wrote: They must be selling at half price. Merus only pays 5-6 x ebitda for assets and Cxr paid double that. Not a good sign.
peter75 wrote: Cxr is selling a piece of pharma to merus labs in england
sems the buyers don't want all of England